Hostname: page-component-7b7567c8c-w7t8q Total loading time: 0 Render date: 2026-11-18T20:26:59.488Z Has data issue: false hasContentIssue false

64 Synthetic data generation using generative AI to support biomedical innovation: A health policy perspective

Published online by Cambridge University Press:  08 May 2026

Rachele Hendricks-Sturrup
Affiliation:
Duke University, Duke-Margolis Institute of Health policy
Maryam Nafie
Affiliation:
Duke University, Duke-Margolis Institute of Health policy
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Objectives/Goals: Synthetic data holds potential for inclusion in medical product development pipelines. Therefore, we explored the current regulatory and practice landscape to identify best practices used to ensure, and communicate to key stakeholders, synthetic data quality, relevance, and reliability in regulatory settings. Methods/Study Population: We identified areas in which synthetic data created using generative AI holds the most value for health researchers. We reviewed regulatory documents, published literature, and expert insights to examine how regulators currently use, define, apply, and govern synthetic data created using generative AI. Next, we identified data management tools, best practices, ethical considerations, and regulatory developments that are necessary for generating fit-for-use synthetic datasets. Using this information, we developed a risk-based credibility assessment framework that aligns with current governmental standards that can be useful for users of synthetic data derived from generative AI applications in regulatory settings. Results/Anticipated Results: Synthetic data created using generative AI holds value for health researchers across four key areas: Acting as a 1) privacy-enhancing technology, 2) data science ’sandbox’ for training and exploration, 3) mechanism to navigate legalities around data sharing and/or use, and 4) method to augment underrepresented subgroups in datasets. However, synthetic data raise ethical and legal concerns, particularly regarding privacy, consent, stakeholder engagement, and ownership. Regulators and health technology assessment bodies, including FDA, EMA, MHRA, and Canada’s Drug Agency, are exploring synthetic data to supplement medical datasets, validate external control arms, enhance model performance, and inform regulatory decision-making. Discussion/Significance of Impact: Our work underscores the need to continue cultivating transparent, ethical, and fit-for-use approaches to synthetic data generation using generative AI. Moving forward, effective synthetic data use and development requires a culture of learning and transparency among regulators, end users, and those involved in data generation and exchange.

Information

Type
AI and Data Science
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
Copyright
© The Author(s), 2026. The Association for Clinical and Translational Science